CSL (OTCMKTS:CSLLY) Raised to “Strong-Buy” at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of CSL (OTCMKTS:CSLLY) to a strong-buy rating in a research report released on Thursday,Zacks.com reports.

CSL Price Performance

Shares of CSLLY opened at $86.16 on Thursday. The stock has a fifty day moving average price of $89.07 and a 200 day moving average price of $96.46. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.97 and a current ratio of 2.18. CSL has a 12 month low of $83.31 and a 12 month high of $109.00.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.